In addition, since the first evidence of a beneficial effect of GLP-1RAs in BAD treatment was not available until 2019, we notice that the prescriptions of GLP-1RAs up until this year were made for other indications than BAD in contrast to bile acid sequestrants
Youre not just picking between two similar choices
The MDL is meant to centralize all semaglutide lawsuits involving gastroparesis injuries into one court, under one judge: Each lawsuit contains substantially similar allegations about GLP-1 RAs (specifically, Ozempic, Wegovy, Rybelsus, Trulicity, and/or Mounjaro) and their alleged propensity to cause gastrointestinal injuries. All of these lawsuits share common issues of fact regarding: If defendants knew or should have known that their GLP-1 RA products can cause gastroparesis and other gastrointestinal injuries Whether defendants adequately warned plaintiffs or their prescribing physicians about the alleged dangers of these products Whether defendants made false, misleading, or incomplete representations regarding the safety of these products
Bands of scar tissue developing between the abdomen and other organs can create abnormal connections (fistulas), resulting in pain, constipation, and intestinal blockage
.png.jpg)
